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Abstract
Background: To evaluate the U.K. Prospective Diabetes Study (UKPDS) and Framingham risk equations for
predicting short-term risk of coronary heart disease (CHD) events among adults with long-standing type 2 diabetes,
including those with and without preexisting CHD.
Methods: Prospective cohort of U.S. managed care enrollees aged ≥ 18 years and mean diabetes duration of more
than 10 years, participating in the Translating Research into Action for Diabetes (TRIAD) study, was followed for the
first occurrence of CHD events from 2000 to 2003. The UKPDS and Framingham risk equations were evaluated for
discriminating power and calibration.
Results: A total of 8303 TRIAD participants, were identified to evaluate the UKPDS (n = 5914, 120 events),
Framingham-initial (n = 5914, 218 events) and Framingham-secondary (n = 2389, 374 events) risk equations,
according to their prior CHD history. All of these equations exhibited low discriminating power with Harrell’s
c-index <0.65. All except the Framingham-initial equation for women and the Framingham-secondary equation for
men had low levels of calibration. After adjsusting for the average values of predictors and event rates in the TRIAD
population, the calibration of these equations greatly improved.
Conclusions: The UKPDS and Framingham risk equations may be inappropriate for predicting the short-term risk of
CHD events in patients with long-standing type 2 diabetes, partly due to changes in medications used by patients
with diabetes and other improvements in clinical care since the Frmaingham and UKPDS studies were conducted.
Refinement of these equations to reflect contemporary CHD profiles, diagnostics and therapies are needed to
provide reliable risk estimates to inform effective treatment.
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Background
Adults with diabetes have an increased risk of coronary
heart disease (CHD) [1,2]. Their risks of having an initial
CHD event and the prediction equations used to deter-
mine this risk have been extensively studied [3-12].
These risk estimates are helpful for clinical consultation
and identifying high risk populations for effective treat-
ment. Recent studies even recommended that the initi-
ation of cardio-protective treatment for diabetic patients
be based on personalized CHD risk estimates to reduce
harms from overly aggressive risk factor modification
[13,14]. Several equations are currently available to esti-
mate CHD risk. Among them are algorithms derived for
use in the general population such as the Systematic
Coronary Risk Evaluation (SCORE) [15], QRISK [16,17],
the Reynolds Risk Score for women [18] and the Fra-
mingham risk equations [4,6]. Most of these algorithms
include diabetes as a risk factor when determining CHD
risk. Algorithms particularly developed for use in dia-
betic populations include the United Kingdom Prospect-
ive Diabetes Study (UKPDS) risk equations [3] and a
recent algorithm developed by Donnan et al. [10].
Among these algorithms, the UKPDS and Framingham
equations [3,4] are frequently used to predict the risk of
an initial CHD event for diabetic patients. Their use has
also been recommended in national guidelines in various
regions [19-23]. However, previous studies have shown
that both the UKPDS and Framingham risk equations
can give unreliable risk estimates of an initial CHD event
for diabetic patients in some European and Australian
cohorts [7,9,11,24,25]. Given the variation in practice
patterns, patient racial/ethnic composition between
these regions and the U.S., as well as changes in the
standards of clinical care for patients with diabetes over
the last few decades, it is not clear whether these equa-
tions can provide reliable risk estimates for adults with
long-standing diabetes in the U.S. Recent estimates
showed that approximately 785,000 Americans will have
a new coronary event each year, with approximately
470,000 of them a recurrent event [26]. It is of both clin-
ical and public health importance to understand and re-
evaluate the risk stratifications for patients with long-
standing type 2 diabetes.
In this paper, we evaluate the performance of the
UKPDS [3] and Framingham initial CHD risk equations
[4] in predicting CHD occurrence for adults with long-
standing type 2 diabetes without an established CHD
history. We also evaluated the performance of the sec-
ondary Framingham risk equation [27] in predicting
CHD events among those with an established CHD his-
tory as this has not been studied among adults who have
diabetes. Because adults with long-standing diabetes are
known to have higher CHD risk than those without dia-
betes or newly diagnosed with diabetes, we focused on
estimates of short-term CHD event risk using data from
the Translating Research Into Action for Diabetes
(TRIAD) study, a large multi-center, population-based,
prospective study of diabetic adults [28].
Methods
The TRIAD study has been described in detail elsewhere
[28]. In brief, the initial TRIAD cohort consisted of
11927 community-dwelling adults with diabetes ages
18 years and older, and continuously enrolled between
July 2000 and August 2001 in one of 10 managed care
plans in 7 states. TRIAD data included patient surveys,
medical record reviews, health plan administrative
claims (inpatient, outpatient and emergency room
claims), and National Death Index (NDI) data. In our
analyses, we limited our sample to the 8820 TRIAD par-
ticipants for whom we had medical record data
18 months prior to the baseline survey. In addition, we
excluded those whose age at diabetes diagnosis was less
than 30 years and were treated with insulin only at the
time of the baseline survey since it is likely they had type
1 diabetes. Institutional review boards at each participat-
ing site approved the study and all participants provided
informed consent.
Risk predictors such as patient age, diabetes duration
(years since diagnosis), and smoking status were
obtained from survey responses. Hemoglobin A1C, sys-
tolic blood pressure, diastolic blood pressure, total chol-
esterol, HDL, and LDL were obtained from medical
records, and only the most recent values within the
18 months prior to the baseline survey were used.
Patients were defined as having a CHD history if at least
one of the following conditions was documented in their
medical records within 3 years prior to the baseline sur-
vey: angina, MI, coronary heart disease, coronary artery
disease, coronary angioplasty or coronary bypass. We
also obtained additional baseline information on diabetes
treatment from patient surveys, and determined the use
of hypertension medication, statins and co-morbid con-
ditions (measured by the Charlson’s score [29,30]) from
medical records from 5 out of the original 6 research
centers where the data were available to us.
Outcome variables
For evaluation of each risk equation, we used the CHD
event definition used in the study that provided the
equations. To evaluate the UKPDS risk equations, we
defined a CHD event as: a fatal or nonfatal MI (ICD-
9-CM code of 410.xx administrative data; ICD-10 of
I21-I22 NDI data); to evaluate the Framingham risk
equations, we defined a CHD event as: angina pectoris,
MI, coronary insufficiency, sudden death, or CHD
death (ICD-9-CM code of 410.xx, 413, 411.89, 414.8
administrative data; ICD-10 of I20-I22 and I46.1 NDI
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data). For each CHD event, we calculated the “CHD
event time” as the time from the TRIAD baseline sur-
vey to the first CHD event. Observations were cen-
sored at the end of 2003, date of death from another
cause, or the date of the first health plan enrollment
gap of more than two months, whichever came first.
UKPDS and Framingham CHD risk equations
We evaluated various versions of UKPDS, Framingham
initial and Framingham secondary CHD risk equations
(Table 1). Specifically, two UKPDS risk equations were
evaluated: The first equation predicts the risk of an ini-
tial CHD event for a patient with newly diagnosed dia-
betes and we referred to it as the incident UKPDS risk
equation. The second equation takes into account dia-
betes duration when predicting the risk of an initial
CHD event and we thus referred to it as the duration
UKPDS risk equation. Framingham risk equations are
gender-specific and were thus evaluated separately for
men and women. We evaluated the risk equations for
predicting an initial CHD event using total cholesterol
categories and referred to it as Framingham-initial. We
also evaluated the performance of the equations for pre-
dicting a subsequent CHD event and referred to it as the
Framingham-secondary.
Risk score calculation and statistical methods
For each eligible participant, we calculated the absolute
risk of a CHD event using each equation. Because the
racial/ethnic composition of the TRIAD cohort differed
from that in the UKPDS cohort, we used the “Afro-
Caribbean” risk adjustment for African American
patients and the “Caucasian or Asian-Indian” calculation
adjustment for the remaining participants. Framingham
risk equations were not adjusted for race/ethnicity. Be-
cause the Framingham-initial equations were published
with the 10-year baseline survival rates, we obtained the
1–5 year baseline survival rates directly from the Fra-
mingham investigators.
We evaluated the risk equations for 1) how well they
separate individuals who develop a CHD event from
those who do not (discrimination) and 2) how close pre-
dicted risks are to observed risks [6,31] (calibration, or
goodness-of-fit (GOF)). When we examined the per-
formance of the UKPDS and Framingham-initial CHD
equations, we only included patients without a CHD his-
tory; when we examined the performance of the
Framingham-secondary equations, we only included
patients with a CHD history.
Discrimination was evaluated using the Harrell’s c-
index for censored data (R package HMISC available on
CRAN at http://cran.r-project.org), a statistic similar to
the area under a receiver operating characteristic curve
[32]. In general, a c-index greater than 0.7 indicates good
discrimination while a value of 0.5 indicates discrimin-
ation equivalent to chance. Intermediate values indicate
limited discriminating utility. Calibration plots were gen-
erated and Hosmer-Lemeshow-type chi-square statistics
[6,33] were calculated to compare differences between
predicted and observed risks based on deciles of risk
scores. We conservatively defined lack of calibration as
chi-square values greater than 23.2 (the 99th percentile
of chi-square distribution with 10 degrees of freedom).
We also recalibrated the UKPDS and Framingham risk
equations by replacing the average values of predictors
and event rates in the original populations by those in
the TRIAD population. Specifically, we used the method
of D’Agostino et al. [6] to recalibrate the Framingham-
Table 1 UKPDS and framingham risk equations
Equations Formula for t-year CHD risk
UKPDS Incident
Stevens et al. [3]
1 exp q 1 dtð Þ=1 df g;where d = 1.078 and logeq =−4.4918+ 0.0573× (age-55)−0.6444× female-0.9416×
Afro-Caribbean + 0.3001× smoking+ 0.1681× (HbA1c-6.72) +0.0843× (SPB-135.7)/10 + 1.3468× {loge(TC
a/HDL)-1.59}.
UKPDS Duration 1 exp qdT 1 dtð Þ=1 d ;where T = diabetes duration in years, and d and q were defined as above.
Framingham-Initial
Table 6 in
Wilson et al. [4]
Male 1 S0 tð Þ exp mð Þ;where m= 0.0483×Age-0.6595× (TCa < 160 mg/dL) + 0.1769×(TC 200-239 mg/dL) + 0.5054×
(TC 240-279 mg/dL) + 0.6571×(TC>= 280 mg/dL) + 0.4974×(HDL < 35 mg/dL) + 0.2431× (HDL 35-44 mg/dL)-0.0511×
(HDL 50-59 mg/dL)-0.4866× (HDL >=60 mg/dL)-0.0023×(BP Optimal) + 0.2832× (BP High-normal) + 0.5217×
(BP Stage-I-hypertension) + 0.6186×(BP Stage-II-IV-hypertension) + 0.4284×Diabetes + 0.5234× (Smoker)-3.0975
S0(1)
b =0.9946, S0(2) = 0.9850, S0(3) = 0.9770, S0(4) = 0.9622, S0(5) = 0.95592.
Female 1 S0 tð Þ exp mð Þ;where m= 0.3377×Age-0.0027×age2-0.2614×(TCa < 160 mg/dL) + 0.2077×(TC 200-239 mg/dL)+
0.2439×(TC 240-279 mg/dL) + 0.5351×(TC>=280 mg/dL)+0.8431×(HDL< 35 mg/dL) + 0.3780×(HDL 35-44 mg/dL)+0.1979×
(HDL 45-49 mg/dL)-0.4295×(HDL>=60 mg/dL)−0.5336×(BP Optimal)-0.0677×(BP High-normal)+0.2629×
(BP Stage-I-hypertension) + 0.4657×(BPStage-II-IV-hypertension) + 0.5963×Diabetes+ 0.2925×(Smoker)-9.9255
S0(1)
b =0.9984, S0(2) = 0.9933, S0(3) = 0.9909, S0(4) = 0.9858, S0(5) = 0.98297.
Framingham-
Secondary
Male 1 exp  exp loge tð Þ m½ =0:9994f gð Þ;where m= 4.995–0.0145×age–0.6738× loge (TCa/HDL)-0.3042×Diabetes.
D’Agostino et al. [27]
Female 1 exp  exp loge tð Þ m½ =1:0313f gð Þ;where m= 13.537-0.0225×age−0.834×loge(TCa/HDL)-1.3713×ln(SBP)-
0.7829×Diabetes-0.3669×smoker.
aTC= Total Cholesterol.
bS0(t) represents the estimate of the t-year baseline survival rate, provided by Framingham investigators, for t = 1,2,. . .,5 years.
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initial equations and the method of van Houwelingen
[34] to recalibrate the UKPDS and Framingham-
secondary equations because the latter were parametric
models.
To investigate the difference between study popula-
tions with regard to the effect of risk predictors, we fit-
ted each of these equations on TRIAD data and
compared the estimates of relative risk (hazard ratio)
using the method described in D’Agostino et al. [6]. Spe-
cifically, we fitted the Cox regression models and used
the same CHD event definition as well as the risk pre-
dictors in the original equations. For simplicity, the
models using the TRIAD data were all referred to as the
TRIAD models. Regression coefficients, hazard ratio
(HR) estimates, Harrell’s c-index and GOF statistics [35]
were calculated.
Missing data ranged from 1.3% (smoking) to 20.7%
(HDL), and was handled in the data analysis using mul-
tiple imputation. Imputations were generated using a se-
quential regression imputation method via the software
package IVEware, and results were combined using
Rubin’s rule implemented in SAS v9.2 MIANALYZE
procedure [36-38].
Results and discussion
Results
The follow-up time ranged from 0–3.5 years with a me-
dian of 2.7 years (inter-quartile range = 0.9). In the over-
all TRIAD sample (n = 8303 subjects), there were 319
UKPDS-defined and 592 Framingham-defined CHD
events. Among those without a history of CHD
(n = 5914), there were 120 UKPDS-defined and 218
Framingham-defined CHD events over the analysis
period, with a corresponding 3.5-year CHD event rate
(Kaplan-Meier estimate) of 3.0% (95%CI: 2.3%, 3.8%)
and 5.1% (95%CI: 4.2%, 6.0%), respectively. Mean age at
baseline was 59.8 (SD= 12.3) years with a mean diabetes
duration of 10.6 (SD= 9.1) years; 56.7% were female,
39.7% were non-Hispanic White, and nearly 18% were
smokers. Of those for whom we had information on
medication use and co-morbid burden (n = 4602), 78.4%
took oral medication, 26.4% took insulin, 68.7% took
hypertension medication, 28% took statins, and 50% had
a Charlson score > =2. For those with a prior CHD his-
tory (n = 2389), there were 199 UKPDS-defined and 374
Framingham-defined CHD events, with a corresponding
3.5-year CHD event rate of 11.9% (95%CI: 9.6%, 14.2%)
and 20.9% (95%CI: 17.9%, 23.9%), respectively. Com-
pared to those without a CHD history, they were gener-
ally older with longer diabetes duration and better
cholesterol control; they also took more hypertension
medication, statins, and suffered from a greater number
of comorbid conditions (Table 2).
Table 2 Demographics and clinical characteristics of
TRIAD participants
Without CHD
History
With CHD
History
N 5914 2389
Age at baseline survey (SD) (years) 59.8 (12.3) 66.1 (10.4)
Female (%) 56.7 44.9
Race/Ethnicity (%)
Non- Hispanic white 39.7 51.0
Non- Hispanic black 17.3 15.9
Hispanic 17.7 14.4
Hawaiian/Pacific Islander 16.6 10.5
Other 8.8 8.2
Duration (SD) (years) 10.6 (9.1) 13.6 (10.2)
History of CHD eventa (%) 0.0 100.0
HbA1C (SD) 8(1.9) 7.9(1.8)
Total Cholesterol (SD) (mg/dL) 200.8 (42.1) 191.9 (45.5)
HDL Cholesterol (SD) (mg/dL) 47.5 (12.9) 44.7 (12.8)
LDL Cholesterol (SD) (mg/dL) 116.1 (34.9) 108.8 (36.7)
Systolic Blood Pressure (SD) (mmHg) 136.4 (18.4) 136.7 (19.8)
Smoker (%) 18.5 17.5
Diabetes Treatmentb (%)
Diet only 7.6 6.2
Oral medication 66.0 57.5
Insulin 14.0 20.1
Insulin and oral medication 12.4 15.4
Other medicationb (%)
Hypertension 68.7 88.5
Statin 28.0 54.6
Co-morbidity Charlson’s scoreb (%)
<1 5.2 1.9
> = 1 to 2 44.0 17.4
> = 2 to 3 28.9 24.1
> = 3 21.9 54.6
Number of incident UKPDS
CHD eventsc
120 199
Number of incident Framingham
CHD eventsd
218 374
3.5-year UKPDS CHD event
rate (95%CI)
3.0% 11.9%
(2.3%, 3.8%) (9.6%, 14.2%)
3.5-year Framingham CHD event
rate (95%CI)
5.1% 20.9%
(4.2%, 6.0%) (17.9%, 23.9%)
aCHD history was identified in the medical record documentation, if at least
one of the following conditions occurred in medical records 3 years prior to
the baseline survey: angina, MI, other coronary heart disease or coronary
artery disease, coronary angioplasty or bypass.
bData were obtained from 4602 patients without a CHD history and 2029
patients with a CHD history.
cUKPDS CHD event is defined as fatal or non-fatal MI.
dFramingham CHD event is defined as angina pectoris, MI, coronary
insufficiency, sudden or non-sudden CHD death.
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Evaluation of discrimination and calibration of the
UKPDS and Framingham risk equations is summarized
in Table 3. The Harrell’s c-index of discrimination for
the UKPDS risk equations was generally low: 0.63 (95%
CI: 0.58, 0.68) for the incident equation and 0.64 (95%
CI: 0.59, 0.69) for the duration equation. The (un-
adjusted) GOF chi-square value for both UKPDS equa-
tions exceeded the established cutoff, indicating a lack
of calibration. Specifically, these equations tended to
over-estimate CHD risk (Figure 1). Similar results were
found in our evaluation of Framingham-initial and
Framingham-secondary risk equations. Specifically, we
found that discrimination was generally low, and so was
the calibration except the Framingham-initial equation
for women and the Framingham-secondary equation for
men. When using these equations, risk tended to be
over-estimated for men without a CHD history, and
under-estimated for women with a CHD history. After
recalibration, the goodness-of-fit of all of the risk equa-
tions greatly improved as indicated by the adjusted
GOF chi-square statistics that are below the cutoff
values (Table 3 and Figure 1).
For the TRIAD version of the UKPDS equations
(Table 4), only age and systolic blood pressure remained
significantly associated with CHD (p<0.05). HRs asso-
ciated with age, gender, racial difference, loge(total chol-
esterol/HDL) and diabetes duration were significantly
different, mostly smaller, than those in the original equa-
tions (p<0.05). For the TRIAD versions of Framingham
initial and secondary equations, almost none of the risk
predictors were significantly associated with CHD. Most
HR estimates did not significantly differ from those from
the original estimates, except for age and HDL for
women in the initial equation. However, because the
standard errors of regression coefficient estimates for
the original Framingham-initial equations were not pro-
vided in Wilson et al. [4], thus they were not included in
these calculations and the actual p-value might be
slightly bigger. The goodness-of-fit of these TRIAD
models is generally good (p<0.05), but the discriminating
power was low (all the c-indexes were < 0.65).
Discussion
Our study showed that the UKPDS and Framingham
risk equations may be inappropriate for predicting short-
term risk of CHD events for adults with long-standing
type-2 diabetes. All of these equations exhibited low dis-
criminating power. All except the Framingham-initial
equation for women and Framingham-secondary equa-
tion for men had low levels of calibration. Our findings
were similar to those found in other studies, including
van Dieren et al. [9] that evaluated the performance of
the UKPDS risk equations by looking at the CHD event
risk at 4, 5, 6 and 8 years, and the ADVANCE trial that
evaluated the 4-year CHD risk [11]. Separate analyses
also showed that the UKPDS and Framingham-initial
equations tended to greatly underestimate the risk of a
CHD event for patients with a CHD history and discrim-
inating power was consistently low (data not shown).
Several factors may explain our findings of low dis-
crimination and calibration of these equations. First,
our study participants had an average of diabetes dur-
ation longer than ten years and were community-based
health plan enrollees. In contrast, the UKPDS cohort
was derived from a clinical trial that only included indi-
viduals newly diagnosed with diabetes, while the Fra-
mingham cohort only included a small proportion of
individuals with diabetes. The general health status, pat-
terns of medication use, and presence of other CHD
risk factors in the TRIAD cohort (Table 1) likely differ
from those in the previous studies. For instance, at least
68% of TRIAD participants received anti-hypertensive
therapy, while fewer than 30% of UKPDS participants
and fewer than 10% of Framingham participants had
received anti-hypertensive therapy [4,39]. Moreover, the
participants in TRIAD were on average 10 years older
than those in the UKPDS and Framingham cohorts
[3,4]. Risk estimates of these equations may need ad-
justment when applied to older patients because older
patients generally are more susceptible to cardiovascu-
lar risks, such as higher blood pressure and declining
levels of physical activity. They also tend to have more
co-morbid conditions, both physically and mentally;
some co-morbid conditions may even lead to non-
cardiovascular deaths as competing risks [40-42]. In
addition, the racial/ethnic composition of our cohort
included greater numbers of non-white patients than
the UKPDS or Framingham cohorts. Risk profiles of
minority groups not specified by the algorithms (e.g.,
Hispanics and Asians other than South Asians) may be
significantly different. Finally, UKPDS and Framingham
risk equations were developed from cohorts formed be-
tween the 1970s and the 1990s [3,4]. Treatment of type
2 diabetes and management of cardiovascular risk
among diabetic adults have improved substantially since
then [43-46].
In investigating the relations of these risk equations with
the risk of CHD events in the TRIAD cohort, we found
that most predictors were not statistically significant in
the TRIAD models. This may be caused by patterns of
medication use (e.g., hypertensive drugs, diabetes treat-
ment and statins; Table 1), comorbid conditions, or other
factors unaccounted for in the risk equations. Some recent
algorithms do include medication as a predictor, such as
the prediction model of Donnan et al. [10]. To improve
the discriminating power of these models, additional vari-
ables, such as medications, family history, life-style related
risk factors, socioeconomic status, co-morbid conditions,
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and novel biomarkers [20,26,45,47,48], may need to be
incorporated in the risk equations.
Recent studies suggest that using a “blanket” approach
or aggressive risk factor modification (e.g., lowering LDL
and/or blood pressure), based on the public notion that
diabetes is a CHD risk equivalent, may lead to an overly
aggressive treatment and thus offset a patient’s net bene-
fit from treatment [13,14,49]. These authors instead rec-
ommend that patients be treated based on appropriate
personalized CHD risk estimates. Our analysis showed
that the UKPDS and the Framingham-initial equation
for men tend to overestimate the initial CHD risk for
diabetic patients in a contemporary cohort. Refinement
of these equations to reflect the CHD prognostics in a
modern diabetic cohort are needed to provide reliable
risk estimates to inform effective treatment.
The strength of our study is the large sample size.
However, our study has some limitations. The longest
follow-up time for CHD events in our study was
3.5 years, thus limiting our ability to evaluate the use of
these equations to predict longer-term CHD event risk.
With longer follow-up (e.g., 10 years), it is possible that
these equations may provide better predictions of CHD
risks. However, our study population is more susceptible
to CHD than the general population, and the average
age of our study population tends to be older
(> = 60 years). Evaluating short-term CHD risk in this
population can provide useful insights for disease
Table 3 Discrimination and calibration of UKPDS and Framingham CHD Risk Equations
N (Number of
CHD events)
Discrimination Harrell’s
c-index (95%CI)
Calibration GOF Chi-Square Statistics
Unadjusteda Adjusteda
UKPDS Incident 5914 (120) 0.63 (0.58, 0.68) 55.64 2.18
Duration 5914 (120) 0.64 (0.59, 0.69) 446.73 7.65
Framingham-Initial Men 2560 (97) 0.61 (0.55, 0.67) 24.28 0.88
Women 3354 (121) 0.59 (0.54, 0.64) 17.27 5.85
Framingham-Secondary Men 1317 (209) 0.55 (0.51, 0.59) 19.45 8.52
Women 1072 (165) 0.54 (0.49, 0.58) 77.59 5.23
aUnadjusted and adjusted refer to the GOF chi-square statistics before vs. after recalibration, respectively.
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Figure 1 Calibration plot of UKPDS and Framingham CHD risk equations. X-axes refer to deciles of predicted risk scores using the UKPDS
and Framingham CHD risk equations, where appropriate. Each bar in the graph represents the average of the observed and predicted risk scores
from the UKPDS and Framingham risk equations.
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Table 4 Regression coefficients, hazard ratio (HR), and goodness-of-fit of TRIAD Models and comparisons of the hazard
ratios with the original risk equations
TRIAD models Original
Model Variable Coeff Standard Error or 95%CI p-value HR HR
Incident Age (year) 0.038 0.008 <.0001 1.038* 1.059
UKPDS Female (yes/no) −0.109 0.188 0.561 0.896* 0.525
African American (yes/no) −0.154 0.281 0.585 0.858* 0.390
Smoker (yes/no) 0.440 0.235 0.061 1.552 1.350
HbA1c 0.075 0.054 0.170 1.077 1.183
SBP 0.010 0.005 0.034 1.010 1.008
loge (TC
a/HDL) 0.588 0.359 0.102 1.801* 3.845
C index 0.66 (0.61, 0.71)
p-value for GOF 0.48
Duration
UKPDS Age (year) 0.035 0.009 <.0001 1.035* 1.059
Female (yes/no) −0.122 0.188 0.517 0.885* 0.525
African American (yes/no) −0.160 0.281 0.569 0.852* 0.390
Smoker (yes/no) 0.450 0.235 0.055 1.568 1.350
A1c 0.066 0.055 0.234 1.068 1.183
SBP 0.010 0.005 0.037 1.010 1.008
loge (TC
a/HDL) 0.612 0.358 0.089 1.844 3.845
Duration (year) 0.012 0.009 0.177 1.012* 1.078
C index 0.66 (0.61, 0.71)
p-value for GOF 0.62
Framingham
-Initial Age (year) 0.037 0.009 <.0001 1.038 1.049
Male TC, mg/dL
<160 −0.154 0.385 0.690 0.857 0.517
160-199 - - - - -
200–239 0.415 0.239 0.083 1.514 1.194
240-279 0.052 0.422 0.903 1.053 1.658
≥280 −0.228 1.055 0.829 0.796 1.929
HDL, mg/dL
<35 −0.004 0.355 0.990 0.996 1.645
35-44 −0.179 0.306 0.560 0.836 1.275
45-59 - - - - -
50-59 −0.297 0.397 0.455 0.743 0.950
≥60 −0.272 0.465 0.558 0.762 0.615
Blood Pressureb
Optimal −0.513 0.459 0.264 0.599 0.998
Normal - - - - -
High normal −0.059 0.326 0.857 0.943 1.327
Hypertension stage I 0.037 0.299 0.903 1.037 1.685
Hypertension stage II–IV −0.009 0.376 0.982 0.991 1.856
Smoker 0.216 0.273 0.429 1.241 1.688
Lu et al. BMC Endocrine Disorders 2012, 12:12 Page 7 of 10
http://www.biomedcentral.com/1472-6823/12/12
Table 4 Regression coefficients, hazard ratio (HR), and goodness-of-fit of TRIAD Models and comparisons of the hazard
ratios with the original risk equations (Continued)
C index 0.65 (0.59, 0.70)
p-value for GOF 0.53
Framingham
-Initial Age (year) 0.157 0.080 0.050 1.170* 1.402
Female Age2 (year) −0.001 0.001 0.103 0.999 0.997
TC, mg/dL
<160 −0.759 0.547 0.168 0.468 0.77
160-199 - - - - -
200–239 −0.072 0.233 0.756 0.930 1.231
240-279 0.302 0.302 0.318 1.353 1.276
≥280 0.693 0.356 0.052 1.999 1.708
HDL, mg/dL
<35 0.415 0.461 0.369 1.515 2.324
35-44 0.132 0.291 0.652 1.141 1.459
50-59 0.210 0.336 0.534 1.233 1.219
50-59 - - - - -
≥60 0.372 0.269 0.167 1.451** 0.651
Blood Pressureb
Optimal −0.638 0.469 0.174 0.528 0.586
Normal - - - - -
High normal −0.298 0.318 0.348 0.742 0.935
Hypertension stage I 0.119 0.270 0.660 1.126 1.301
Hypertension stage II–IV 0.340 0.301 0.259 1.404 1.593
Smoker 0.440 0.236 0.062 1.553 1.340
C index 0.67 (0.63, 0.72)
p-value for GOF 0.62
Framingham
-Secondary Age (year) 0.006 0.007 0.426 1.005 1.015
Male loge(TC
†/HDL) 0.604 0.261 0.023 1.827 1.962
C index 0.55 (0.51, 0.59)
p-value for GOF 0.27
Framingham
-Secondary Age (year) 0.012 0.008 0.131 1.012 1.022
Female loge (TC
†/HDL) 0.336 0.335 0.319 1.395 2.245
loge (SBP) 0.793 0.560 0.157 2.248 3.780
Smoker (yes/no) −0.266 0.240 0.269 0.764 1.427
C index 0.55 (0.50, 0.59)
p-value for GOF 0.23
aTC = Total Cholesterol.
bBlood Pressure categories (mmHg): Optimal: Systolic < 120, Diastolic <80; Normal: Systolic 120–129, Diastolic <80-84; High normal: Systolic 130–139, Diastolic
85–89; Hypertension stage I: Systolic 140–159, Diastolic 90–99, Hypertension stage II–IV: Systolic≥ 160, Diastolic ≥100 [4].
*p<0.05, **p<0.01, ***P<0.001 in the HR comparisons of the TRIAD models with original models. Note that in comparing HRs with the Framingham-initial
equations, the actual p-values may be slightly bigger than those reported here because the standard errors of the original regression coefficient estimates were
not provided in original study [4] and they were not included in these calculations.
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management and treatment. Since CHD events were
identified mostly through health plan administrative
data, identification of these events may not be complete
[50], particularly for patients with “silent” infarction who
do not seek health care and thus are not represented in
claims data. As a consequence, while the numbers of
CHD events represent what a health plan should expect
from a typical diabetic patient population, it will miss
events that are not clinically recognized.
Conclusion
Our study shows that UKPDS and Framingham CHD
risk equations may have limited utility to predict CHD
risk for adults with long-standing type-2 diabetes in a
U.S. population. It is of both clinical and public health
importance to understand the risk levels, risk factors,
effective treatment and prevention of the occurrence
of a CHD event. Evaluation of these commonly used
risk equations for predicting short-term risk of CHD
events in this cohort is important in that risk-
stratification is frequently used for clinical decision-
making, and use of these risk equations are likely to
give unreliable risk estimates. In addition, given the
high rates of CHD and recurrent CHD events in adults
with diabetes, refinement of these risk equations may
help to identify high-risk populations that can benefit
from public health approaches to risk reduction. The
number of adults with long-standing diabetes and
associated CHD in the U.S. is high [26,51]. Our find-
ings highlight the need for new or more refined CHD
risk equations to re-assess the CHD event risk and
understand factors that influence CHD event risk in
adults with prevalent diabetes in a modern U.S.
cohort.
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